<DOC>
	<DOC>NCT01385527</DOC>
	<brief_summary>The purpose of this study is to evaluate whether participation in an Internet-based intervention helps improve atopic dermatitis treatment outcomes.</brief_summary>
	<brief_title>Pediatric Atopic Dermatitis (AD) Internet Survey</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Any child age 2 to 8 with a diagnosis of atopic dermatitis confirmed by a dermatologist, together with the child's parent/guardian. Written consent must be given by parent/guardian. Child is less than 2 or greater than 8 years of age. Known allergy or sensitivity to topical triamcinolone in the child. Inability to complete all studyrelated visits, or inability to complete the Internet survey due to inadequate Internet access. Introduction of any other prescription medication, topical or systemic, for atopic dermatitis while participating in the study. Subjects who are on systemic antiinflammatory treatments for atopic dermatitis must be on a stable dose for at least 3 months prior to enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>